What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?

被引：2
|
作者：
Mehanna, Joe [1 ]
Haddad, Fady G. H. [2 ]
Eid, Roland [2 ]
Lambertini, Matteo [3 ,4 ,5 ]
Kourie, Hampig Raphael [2 ]
机构：
[1] St Joseph Univ, Fac Med, Beirut, Lebanon
[2] St Joseph Univ, Hematol Oncol Dept, Fac Med, Beirut, Lebanon
[3] Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium
[4] Inst Jules Bordet, Breast Canc Translat Res Lab, Brussels, Belgium
[5] Univ Libre Bruxelles, Blvd Waterloo 121, B-1000 Brussels, Belgium
来源：
TRANSLATIONAL CANCER RESEARCH | 2018年 / 7卷 / 06期
关键词：
ADJUVANT TRASTUZUMAB; SURVIVAL;
D O I：
10.21037/tcr.2018.09.07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1354 / 1356
页数：3
相关论文
共 50 条
  • [1] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [2] Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (07): : 851 - +
  • [3] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [4] Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Ferraro, Emanuela
    Singh, Jasmeet
    Patil, Sujata
    Razavi, Pedram
    Modi, Shanu
    Chandarlapaty, Sarat
    Barrio, Andrea, V
    Malani, Rachna
    Mellinghoff, Ingo K.
    Boire, Adrienne
    Wen, Hannah Y.
    Brogi, Edi
    Seidman, Andrew D.
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [5] Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Emanuela Ferraro
    Jasmeet Singh
    Sujata Patil
    Pedram Razavi
    Shanu Modi
    Sarat Chandarlapaty
    Andrea V. Barrio
    Rachna Malani
    Ingo K. Mellinghoff
    Adrienne Boire
    Hannah Y. Wen
    Edi Brogi
    Andrew D. Seidman
    Larry Norton
    Mark E. Robson
    Chau T. Dang
    npj Breast Cancer, 8
  • [6] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [7] Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer.
    Knutson, Keith L.
    Clynes, Raphael A.
    Yeramian, Patrick
    Kemp, Kathleen P.
    Shreeder, Barath
    Ballman, Karla V.
    Tenner, Kathleen S.
    Erskine, Courtney L.
    Norton, Nadine
    Northfelt, Donald W.
    Tan, Winston
    Pegram, Mark D.
    Calfa, Carmen Julia
    Mittendorf, Elizabeth Ann
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [9] Evaluation of early cardiotoxicity in HER2-positive breast cancer patients receiving radiotherapy and concurrent trastuzumab
    Aslan, Dicle
    Ozoner, Sadik
    Inanc, Mevlude
    Yildiz, Oguz Galip
    Inanc, Mehmet Tugrul
    IRISH JOURNAL OF MEDICAL SCIENCE, 2025, 194 (01) : 7 - 18
  • [10] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
12345